Skip to main content

Peer Review reports

From: Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy

Original Submission
29 Jun 2022 Submitted Original manuscript
1 Dec 2022 Reviewed Reviewer Report
3 Dec 2022 Reviewed Reviewer Report
19 Dec 2022 Author responded Author comments - Gianluca Furneri
Resubmission - Version 2
19 Dec 2022 Submitted Manuscript version 2
9 Jan 2023 Reviewed Reviewer Report
Resubmission - Version 3
Submitted Manuscript version 3
Publishing
10 Jan 2023 Editorially accepted
16 Jan 2023 Article published 10.1186/s12913-023-09054-x

You can find further information about peer review here.

Back to article page